Skip Navigation

Protein Engineering Design and Selection 2009 22(3):111; doi:10.1093/protein/gzn082
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow A corrigendum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Bradbury, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bradbury, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org

Editorial

Message from the Editors

The first 10% of the full text of this article appears below.

Antibodies remain the highest selling category of biologics, with 26 monoclonal antibodies on the market, reaping a total of $2b in 2007. Most of these are prescribed for cancer and inflammatory disorders, and their combined yearly growth of 22% has led many to believe that monoclonal antibodies are the . . . [Full Text of this Article]

Andrew Bradbury

President, The Antibody Society


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?